Table 2.
Comparisons of β-cell function parameters in the GCK-MODY and type 2 diabetes groups during treatment with dorzagliatin versus placebo
| GCK-MODY group (n = 8) | Type 2 diabetes group (n = 10) | |||||
|---|---|---|---|---|---|---|
| Placebo | Dorzagliatin | P | Placebo | Dorzagliatin | P | |
| Basal glucose (mmol/L) | 5.4 ± 0.3 | 4.6 ± 0.6 | 0.010 | 5.2 ± 0.7 | 4.9 ± 1.0 | 0.411 |
| Steady-state glucose (mmol/L) | 11.9 ± 0.2 | 11.6 ± 0.6 | 0.115 | 11.9 ± 0.2 | 11.9 ± 0.3 | 0.979 |
| AIRg (pmol/L) | 179.4 ± 117.7 | 226.1 ± 64.3 | 0.164 | 31.5 ± 22.1 | −2.3 ± 22.6 | 0.006 |
| SIRg (pmol/L) | 171.3 ± 94.7 | 466.2 ± 263.2 | 0.011 | 142.3 ± 99.8 | 187.1 ± 157.6 | 0.139 |
| ACPRg (pmol/L) | 577.1 ± 363.0 | 675.5 ± 251.1 | 0.334 | 120.9 ± 66.4 | 48.0 ± 58.4 | 0.004 |
| SCPRg (pmol/L) | 1,321.1 ± 433.1 | 2,006.3 ± 523.7 | 0.005 | 1,086.0 ± 380.0 | 1,211.8 ± 430.4 | 0.209 |
| ISI (10−5 ∗ mmol/kg/min per pmol/L) | 13.9 ± 7.3 | 11.9 ± 4.8 | 0.474 | 18.7 ± 22.8 | 20.1 ± 26.2 | 0.430 |
| Cmax-In (pmol/L) | 343.7 ± 194.7 | 392.4 ± 91.5 | 0.441 | 119.2 ± 30.2 | 101.1 ± 50.3 | 0.184 |
| Tmax-In (min) | 4.3 ± 1.3 | 4.6 ± 1.0 | 1.000 | 4.2 ± 2.7 | 4.7 ± 3.0 | 0.496 |
| Cmax-CP (pmol/L) | 1,115.1 ± 544.2 | 1,388.2 ± 509.6 | 0.053 | 710.6 ± 269.1 | 776.3 ± 299.4 | 0.187 |
| Tmax-CP (min) | 6.0 ± 2.1 | 5.5 ± 2.1 | 0.649 | 8.6 ± 1.4 | 7.2 ± 2.9 | 0.242 |
| ISRb (pmol/min/m2) | 57.5 ± 27.6 | 71.8 ± 44.4 | 0.276 | 60.4 ± 41.8 | 102.3 ± 57.0 | 0.018 |
| ISR1abs (pmol/min/m2) | 361.7 ± 210.3 | 443.3 ± 160.0 | 0.148 | 138.1 ± 59.4 | 109.6 ± 41.4 | 0.013 |
| ISR1inc (pmol/min/m2) | 304.2 ± 204.5 | 371.6 ± 141.0 | 0.216 | 77.7 ± 49.8 | 7.3 ± 30.1 | 0.005 |
| ISR2abs (pmol/min/m2) | 271.7 ± 91.3 | 413.6 ± 85.1 | 0.002 | 261.6 ± 101.0 | 296.3 ± 92.6 | 0.097 |
| ISR2inc (pmol/min/m2) | 214.3 ± 74.4 | 341.8 ± 91.1 | 0.004 | 201.2 ± 74.1 | 194.0 ± 49.1 | 0.684 |
| βCGS (pmol/min/m2 per mmol/L) | 33.4 ± 12.6 | 51 ± 20.6 | 0.028 | 30.6 ± 12.8 | 27.7 ± 7.3 | 0.295 |
Data are mean ± SD. Paired samples t test was used for normally distributed data, and Wilcoxon signed rank test was used for nonnormally distributed data. Cmax-CP, maximum concentration of acute C-peptide response; Cmax-In, maximum concentration of acute insulin response; SCPRg, second-phase C-peptide response to glucose; SIRg, second-phase insulin response to glucose; Tmax-CP, time point of maximum concentration of acute C-peptide response; Tmax-In, time point of maximum concentration of acute insulin response.